BlueCross BlueShield of Tennessee Medical Policy Manual

Electrical Impedance Scanning of the Breast

DESCRIPTION

Electrical impedance scanning of the breast involves the transmission of continuous electricity into the body using either an electrical patch attached to the arm or a handheld cylinder. The electrical current travels through the breast where it is then measured at skin level by a probe placed on the breast. It is proposed that cancerous tissue conducts electricity differently than normal tissue; therefore, cancerous images may show up on the resulting imaging as a bright white spot.

An example of an electrical impedance scanning device is the T-Scan™ 2000.  This device received approval for marketing from the U. S. Food and Drug Administration (FDA) in 1999 with the following labeled indication:  “The T-Scan™ 2000 is intended for use as an adjunct to mammography in individuals who have equivocal mammographic findings with ACR Bi-RADS™ categories 3 or 4. In particular, it is not intended for use in cases with clear mammographic or non-mammographic indications for biopsy.

POLICY

IMPORTANT REMINDERS

ADDITIONAL INFORMATION 

There is a lack of evidence in the published literature to show that electrical impedance scanning for the detection and classification of breast lesions can predict clinical events, be used to alter treatment or is effective as or more effective than currently used methods.

SOURCES

Dagler, G., Senol, K., Yakut, Z., Yuksek, Y., Tutuncu, T, Tez, M., & Yesiltepe, C. (2016). Effectiveness of breast electrical impedance imaging for clinically suspicious breast lesions. Bratislavske Lekarske Listy, 117 (9), 505-510. Abstract retrieved June 22, 2017 from PubMed database.

U. S. Food and Drug Administration. (1999, April). Center for Devices and Radiological Health. 510(k) Premarket Notification Database. P970033. Retrieved December 19, 2003 from http://www.fda.gov/cdrh/pdf/p970033.html.

U. S. Food and Drug Administration. (2006, August). Center for Devices and Radiological Health. Advisory Committees. Obstetrics and Gynecology Devices Panel. Retrieved February 10, 2011 from http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ObstetricsandGynecologyDevices/ucm125145.htm.

Vreugdenburg, T., Willis, C., Mundy, L., & Hiller, J. (2013). A systematic review of elastography, electrical impedance scanning and digital infrared thermography for breast cancer screening and diagnosis. Breast Cancer Research and Treatment, 137 (3), 665-676. Abstract retrieved June 22, 2017 from PubMed database.

ORIGINAL EFFECTIVE DATE:  6/1/2004

MOST RECENT REVIEW DATE:  5/9/2019

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.